All In Biotech

Drug Trial Radar · NCT00084136

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial

Last checked: Nov 19, 2026Latest source record: Oct 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,571 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,571

Actual

Start

May 2005

Primary completion

May 2010

Study completion May 2010

Sponsor

Sponsor type
Research network
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Jun 8, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (PI based, or NNRTI based) would not have inferior efficacy compared to the twice daily NNRTI based combination.

Conditions

  • HIV Infections

Interventions

  • AtazanavirDrug

    400 mg taken orally daily

  • Didanosine (enteric-coated)Drug

    400 mg taken orally daily

  • EfavirenzDrug

    600 mg taken orally daily

  • EmtricitabineDrug

    200 mg taken orally daily

  • Emtricitabine/Tenofovir disoproxil fumarateDrug

    200 mg/300 mg taken orally once daily

  • Lamivudine/ZidovudineDrug

    150 mg/300 mg taken orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Treatment Failure (PI Comparison)Time frame: Virologic failure starting 14 weeks following randomization; disease progression starting 12 weeks following randomization; and death occurring at any time following randomization. Follow-up until ddI+FTC+ATV arm closed (May 22, 2008).
  2. Time to Treatment Failure (NRTI Comparison)Time frame: Virologic failure starting 14 weeks following randomization; disease progression starting 12 weeks following randomization; and death occurring at any time following randomization. Follow-up through study closure (May 31, 2010).

Locations

42 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California

  • UCLA CARE Center CRS

    Los Angeles, California

  • Harbor General/UCLA

    Torrance, California

  • Univ. of Colorado Health Sciences Center, Denver

    Denver, Colorado

  • Univ. of Hawaii at Manoa, Leahi Hosp.

    Honolulu, Hawaii

  • Northwestern University

    Chicago, Illinois

  • Rush-Presbyterian/St. Lukes (Chicago)

    Chicago, Illinois

  • Cook County Hospital Core Center

    Chicago, Illinois

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University (St. Louis)

    St Louis, Missouri

  • HIV Prevention & Treatment CRS

    HVTN 722 West 168th Street MSPH Bldg., New York

  • Beth Israel Medical Center

    New York, New York

  • Cornell CRS

    New York, New York

  • NY Univ. HIV/AIDS CRS

    New York, New York

  • Community Health Network, Inc.

    Rochester, New York

  • Univ. of Rochester ACTG CRS

    Rochester, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Wake County Health and Human Services Clinical Research Site

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • The Ohio State Univ. AIDS CRS

    Columbus, Ohio

  • Hosp. of the Univ. of Pennsylvania CRS

    Philadelphia, Pennsylvania

  • Stanley Street Treatment and Resource

    Providence, Rhode Island

  • The Miriam Hosp. ACTG CRS

    Providence, Rhode Island

  • Vanderbilt Therapeutics CRS

    Nashville, Tennessee

  • University of Texas, Southwestern Medical Center

    Dallas, Texas

  • University of Texas, Galveston

    Galveston, Texas

  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS

    Manguinhos, Rio de Janeiro, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Les Centres GHESKIO CRS

    Bicentenaire, Port-au-Prince, Haiti

  • Dr. Kotnis Dispensary

    Pune, India

  • YRG CARE Medical Ctr., VHS Chennai CRS

    Rajiv Gandhi Salai Taramani, Chennai, India

  • NARI Pune CRS

    Pune, Maharashtra, India

  • NARI Clinic at NIV CRS

    Maharashtra State, Pune, India

  • College of Med. JHU CRS

    P.O. Box 1131, Blantyre, Malawi

  • University of North Carolina Lilongwe CRS

    Mzimba Road, Lilongwe, Malawi

  • Asociacion Civil Impacta Salud y Educacion - Miraf CRS

    Barranco, Lima region, Peru

  • San Miguel CRS

    San Miguel, Lima region, Peru

  • Wits HIV CRS

    Johannesburg, Gauteng, South Africa

  • Durban Adult HIV CRS

    Durban, KwaZulu-Natal, South Africa

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.